AbbVie, Teva Pay-For-Delay Deal Draws More Antitrust Claims

Law360, New York (May 8, 2013, 3:54 PM EDT) -- AbbVie Inc. and Teva Pharmaceutical Industries Ltd. were sued Tuesday in Pennsylvania federal court over a patent settlement that allegedly delayed market entry of a generic form of AbbVie's Niaspan cholesterol drug, the latest of several putative antitrust class actions against the companies.

A New York hotel workers union benefits plan lodged a proposed class action challenging a so-called pay-for-delay deal that resolved a patent dispute between two of the drug companies' predecessors. The suit — filed by named plaintiff New York Hotel Trades Council and Hotel Association of New York City Inc. Health Benefits Fund — alleges that the agreement...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!